Department of Medicine, University of California Los Angeles, Los Angeles, 90095.
Curative Inc., San Dimas, CA.
Int J Infect Dis. 2022 May;118:21-23. doi: 10.1016/j.ijid.2022.02.015. Epub 2022 Feb 10.
We aimed to determine the incidence of SARS-CoV-2 infection among individuals with a previous SARS-CoV-2 infection versus vaccinated individuals.
In March 2020, a SARS-CoV-2 testing company began routinely screening its workforce for SARS-CoV-2 with a PCR test. On December 15, 2020, vaccination with either the BNT162b2 or mRNA-1273 vaccines became available. Routine screening has continued through July 2021. We compared the incidence of SARS-CoV-2 infection between people who were SARS-CoV-2 naïve and unvaccinated, people with prior COVID-19 without vaccination, and people vaccinated without prior COVID-19. Incidence in 100 person-years with 95% confidence intervals (95% CIs) was calculated with the Poisson Exact equation. The incidence rate ratio (IRR), the ratio of confirmed COVID-19 cases per 100 person-years of follow-up with 95% CIs, was used as a measure of association between groups. Analyses were performed on StataSE.
The median age of employees was 29.0 years (interquartile range: 23.6, 39.9). During the observation period, 258 SARS-CoV-2 incident infections were identified. The naïve, unvaccinated group had a SARS-CoV-2 incidence of 25.9 per 100 person-years (95% CI: 22.8-29.3). The previously infected, unvaccinated group had an incidence of 0 per 100 person-years (95% CI: 0-5.0). The vaccinated group had an incidence of 1.6 per 100 person-years (95% CI: 0.04-4.2).
We found a strong association between prior SARS-CoV-2 infection and/or vaccination for SARS-CoV-2 with either the BNT162b2 or mRNA-1273 vaccines and the reduced incidence of SARS-CoV-2 infection when compared with those naïve and/or unvaccinated to SARS-CoV-2.
本研究旨在确定既往感染 SARS-CoV-2 与接种疫苗人群中 SARS-CoV-2 感染的发生率。
2020 年 3 月,一家 SARS-CoV-2 检测公司开始常规使用 PCR 检测对其员工进行 SARS-CoV-2 检测。2020 年 12 月 15 日,可使用 BNT162b2 或 mRNA-1273 疫苗进行接种。常规筛查一直持续到 2021 年 7 月。我们比较了 SARS-CoV-2 感染在 SARS-CoV-2 初治且未接种疫苗人群、既往 COVID-19 未经接种疫苗人群和既往 COVID-19 接种疫苗人群中的发生率。采用泊松精确方程计算 100 人年的发病率及其 95%置信区间(95%CI)。发病率比值(IRR),即每 100 人年随访中确诊 COVID-19 病例的比例及其 95%CI,作为组间关联的衡量指标。分析在 StataSE 上进行。
员工的中位年龄为 29.0 岁(四分位间距:23.6,39.9)。在观察期间,共发现 258 例 SARS-CoV-2 感染。初治且未接种疫苗组的 SARS-CoV-2 发病率为 25.9/100 人年(95%CI:22.8-29.3)。既往感染且未接种疫苗组的 SARS-CoV-2 发病率为 0/100 人年(95%CI:0-5.0)。接种疫苗组的 SARS-CoV-2 发病率为 1.6/100 人年(95%CI:0.04-4.2)。
我们发现既往 SARS-CoV-2 感染和/或接种 BNT162b2 或 mRNA-1273 疫苗与 SARS-CoV-2 之间存在很强的关联,与 SARS-CoV-2 初治且未接种疫苗的人群相比,SARS-CoV-2 感染的发生率降低。